Education/ACR/EULAR

Daily EULAR 2025 Recap Day 3 Catch up on the biggest breakthroughs, standout sessions, and expert insights from the third day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology. https://t.co/k0AV4tThWB https://t.co/Z9CVDLg5Tn

Links:

Dr. John Cush @RheumNow( View Tweet )
Safety of Recombinant Zoster Vaccine in Rheumatic Patients New work presented at EULAR focuses on the RZV, which contains recombinant glycoprotein E – the major target of CD4+T-cells. The abstract describes the tolerability and safety of RZV in patients with inflammatory https://t.co/NS3h9CdGIU
Dr. John Cush @RheumNow( View Tweet )
EULAR 2025 – Day 2 Report Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options https://t.co/rys0pA6D6j
Dr. John Cush @RheumNow( View Tweet )
eular

EULAR 2025 – Day 4 Report

Jack Cush, MD

Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. My favorite presentations included the following.

Read Article
RA Care Should be Guided by Need—Not Age Dr. Jiha Lee reports on abstract POS0627, "Examination of Clinical Outcomes by Treatment Duration of Biologics and JAK inhibitors in Nonagenarian Rheumatoid Arthritis," at EULAR 2025 in Barcelona, Spain. https://t.co/zKHXZSVLJy https://t.co/w6CkRy2yIA

Links:

Dr. John Cush @RheumNow( View Tweet )
Health inequities in rheumatology: A central theme This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases (RMDs). Across multiple sessions and studies, delegates are presenting compelling https://t.co/nmdyJYQV0B
Dr. John Cush @RheumNow( View Tweet )
hand stopping falling dominos

Toward Long-Term Prevention of Rheumatoid Arthritis: Are We Closer?

Jonathan Kay, MD

As earlier diagnosis and treatment of rheumatoid arthritis (RA) have resulted in greatly improved clinical outcomes, the focus of current research has now shifted to preventing the development of RA altogether. At EULAR 2025, several oral presentations explored this objective, highlighting data

Read Article
smartphone

Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia

Antoni Chan, MD, PhD

The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence and digital health technologies. At #EULAR2025, the Bechterew-App Trial (LB0002) presented important new data on Axia, a novel AI-powered digital therapeutic developed for axSpA

Read Article
lupus,nephritis,GN

2025 update of EULAR recommendations on lupus nephritis

Md Yuzaiful Md Yusof, MRCP(UK), PhD

At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpas presented a summary of the updated EULAR recommendations on the management of lupus nephritis (LN). The most significant change in the treatment paradigm of LN is that the historic standard of care (SOC) (i.e.

Read Article
Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain https://t.co/xpzeV0oZOr https://t.co/mEYnAFsYQI

Links:

Dr. John Cush @RheumNow( View Tweet )
2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/STmuNO3c2Z
Dr. John Cush @RheumNow( View Tweet )
⌛️ Diagnostic delay in #SpA: Better with time? 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay decreased over time 🔹️Same trends across world regions & across Human Development Index categories POS0908 #EULAR2025 @RheumNow https://t.co/Y9gxQDV9KJ

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
EULAR Points to consider for the definition of D2M and TR #Psoriatic_Arthritis Presented by Dr Helena Marzo-Ortega at #EULAR2025 @RheumNow https://t.co/3LsJvSiXJV

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
Sometimes you hear: “PMR dose steroids don’t really matter” Errrrr… (You wouldn’t accept this steroid exposure in any other disease. Never) #EULAR2025 POS0139 @RheumNow https://t.co/o6w2RpaGBj

Links:

David Liew @drdavidliew( View Tweet )
The new (provisional) 2025 EULAR/ACR classification criteria for anti-synthetase syndrome #EULAR2025 @RheumNow https://t.co/X6VjcN8XZe

Links:

David Liew @drdavidliew( View Tweet )
@RheumNow EULAR haemochromatosis arthropathy classification criteria Patrick Kiely: please photograph this and take it back to your communities Patient association lead comes to the microphone, and thanks them for making be seen. 🥲 #EULAR2025 @RheumNow https://t.co/9bqdV0fuPk

Links:

David Liew @drdavidliew( View Tweet )
#WIN in systemic sclerosis (SSc): -Ongoing trials now targeting multiple pathways. -CONQUEST platform may reshape research in Ssc and other autoimmune diseases. -Revised CRISS could replace single organ endpoints for approval. #EULAR2025 @RheumNow https://t.co/kxSeFb5lAU

Links:

Adela Castro @AdelaCastro222( View Tweet )
+RCT in #pSjD #Sjogrens #Disease #Leflunomide + #hydroxychloroquine Vs #PBO 2nd study to show this - same group need to know ▶️what pt to use this in ▶️is there diff organ improvements ⬆️#ESSDAI ⬇️RF ⬇️Ig’s Easy to prescribe ?early, mild dx #EULAR2025 @RheumNow @eular_org https://t.co/JE0VyFRXc6

Links:

Janet Pope @Janetbirdope( View Tweet )
#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

#EULAR vs #ACR #RA #recommendations Do you agree that #ERA pts should receive #glucocorticoids @RheumNow #EULAR2025 @eular_org

Janet Pope @Janetbirdope( View Tweet )

#EULAR2025 Abstr#OP0204 Limitations of #SLE Damage Index (SDI): outdated items definition, missing item & unclear use in children. Revised SDI (SLICC-ACR-LFA) via data-driven and expert patient-doctor consensus is underway. Next steps: validation and including weighting @RheumNow https://t.co/K5rPgXBPrj

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
ARIAA study: longer-term data now High-risk ACPA+ clinically suspect arthralgias abatacept for 6mo, then stop altogether Really impressive long-term effect also noting success of APIPPRA, abatacept flicks off some very early RA, at least for a while #EULAR2025 OP0325 @RheumNow https://t.co/AeRrUKPPiK https://t.co/jtynyD0ioO

Links:

David Liew @drdavidliew( View Tweet )
Highlights @eular_org #EULAR2025 RCTs + in CTD/RA #ILD w #PPF LB0003 Lots of #CAR-T studies in #SARDs Lots of bDMARDs in #SLE #APS #IgG4 #SjD Neurostimulation 👇 ⬇️inflammation ⬇️pain #RA #fibromyalgia #EULAR2025 @RheumNow @eular_org

Janet Pope @Janetbirdope( View Tweet )

EULAR FMF recommendations 2025: still emphasis on colchicine adherence to maximal dose +/- bDMARDs if needed for control +/- csDMARDs for residual chronic MSK involvement new: consider tapering bDMARD if remission >6mo See the treatment algorithm below⬇️ #EULAR2025 @RheumNow https://t.co/Hy6DOKzfUL

Links:

David Liew @drdavidliew( View Tweet )
Despite the evolution of anti-synthetase antibodies, there’s a clear need for better ways to define the disease. Enter the ACR/EULAR CLASS initiative - classification criteria for anti-synthetase syndrome ⬇️ see the next tweet #EULAR2025 @RheumNow https://t.co/Z3rPOt1vlx

Links:

David Liew @drdavidliew( View Tweet )

Recent Blogs

From DNA to PGA

David Pisetsky, MD, PhD
dna
I have been investigating the mechanisms of antinuclear antibody (ANA) expression in SLE since 1978. In this pursuit, I have followed the advice of my first division chief, Dr. Ralph Snyderman, a great academician.  Ralph told me to identify a research focus and make it mine. I think I have done reasonably well in my mission so you can imagine my surprise (and excitement) when, for the Lupus 2025 meeting in Toronto, I was asked to conduct a Meet the Professor session on the Type 1 & 2 model for SLE. Read Post

The War Rheum

Kathryn H. Dao, M.D.
blue and yellow arms and hands
The effects on rheumatologists and their patients living in Ukraine largely have been unseen by the world. At ACR Convergence 2024, I met Dr. Marta Dzhus who practices at St. Michael's Clinical Hospital in Kyiv; she shared her story with me about the humanitarian crisis in rheumatologic care in Ukraine because of the ongoing war. Here is an excerpt of our conversation. Read Post
×